A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

NCT05634369 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Nationwide Children's Hospital

Collaborators